FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
New combination trial firms up Venclexta’s prospects in AMLAbbVie and Roche have been thrown a lifeline for their Venclexta drug in acute myeloid leukaemia (AML), just Share XNew combination trial firms up Venclexta’s prospects in AMLhttps://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/
AbbVie/Roche’s Venclexta fails in confirmatory AML trialAbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial Share XAbbVie/Roche’s Venclexta fails in confirmatory AML trialhttps://pharmaphorum.com/news/abbvie-roches-venclexta-fails-in-confirmatory-aml-trial/
Roche and AbbVie’s Venclexta approved in CLLRoche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for Share XRoche and AbbVie’s Venclexta approved in CLLhttps://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/
AbbVie/Roche seek first-line CLL use for Venclexta comboAbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new Share XAbbVie/Roche seek first-line CLL use for Venclexta combohttps://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/
AbbVie, Roche eye first-line use of Venclexta in leukaemiaAbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into Share XAbbVie, Roche eye first-line use of Venclexta in leukaemiahttps://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/
AbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patientsAbbVie/Roche’s Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, Share XAbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patientshttps://pharmaphorum.com/transversal-categories/clinical/abbvie-roche-s-potential-blockbuster-venclexta-boosted-by-phase-ii-cll-results/
